Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Boosters further reduce the risk of severe illness and can help curb coronavirus transmission.
The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.
Many people who received any of the authorized COVID-19 vaccines are now eligible for an additional dose of their choice.
Third dose OK’d for people over 65, those at risk for severe COVID-19 and those at high risk of exposure to the coronavirus.
This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).
Non-alcoholic fatty liver disease can lead to more severe, potentially fatal liver diseases, including cirrhosis.
Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
Janssen’s single-tablet antiretroviral regimen was approved on July 17.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
A recent study compared birth outcomes among HIV-positive women exposed to various antiretroviral regimens.
Investigators behind the recent study that raised this concern suggest not combining the two until more research can be done.
A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.
A small study of Spanish people with HIV taking Prezista (darunavir) found that cholesterol and triglycerides dropped after the switch.
Here’s a timeline of the highlights.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.